communication between the infection control staff and the medical and nursing teams, and organization of multiple educative workshop sessions. No IMP-13-producing isolates were detected before or after the detection of IMP-13-producing P. monteilii, either in the burn unit or in any other hospital ward. Up until now, P. monteilii infections had not occurred in this hospital and, in contrast to P. putida, are not yet reported in the literature.
Sir, According to the WHO Report 2010, China had the most multidrug-resistant tuberculosis (MDR-TB) cases in 2008, followed by India and Russia, and was ranked 16th in terms of the estimated proportion of primary (5.7%) and acquired (previously treated) MDR-TB cases among the 27 MDR-TB highburden countries. 1 However, our recent drug-susceptibility surveillance results indicated that the prevalence of acquired MDR-TB cases in the Zunyi area, Guizhou province, China, was much higher (45.1%) than the average prevalence of acquired MDR-TB in China (25.6%), but lower than those in the top six MDR-TB high-burden countries (Tajikistan, Kazakhstan, Azerbaijan, Republic of Moldova, Uzbekistan and Lithuania).
To determine the prevalence and trends of drug-resistant TB in the Zunyi area, in order to improve the treatment outcomes of TB patients, 263 Mycobacterium tuberculosis clinical isolates were collected at the Affiliated Hospital of Zunyi Medical College from 2008 to 2010 and used in drug susceptibility testing against rifampicin, isoniazid, streptomycin and ethambutol. We used the proportion method on Lö wenstein -Jensen media with different concentrations of drugs (rifampicin 40 mg/L, isoniazid 0.2 mg/L, streptomycin 4 mg/L and ethambutol 2 mg/L). The standard M. tuberculosis H37Rv strain was used as a control for all testing.
To compare our results with those from other provinces of China, we selected recent survey results from Shanghai 2 and 4 out of the 10 provinces (covering 38% of the total Chinese population) with the highest rates of MDR among new TB cases (5.4%-10.4%), 3 and combined them with ours in Table 1 . Results indicated that the Zunyi area had the highest prevalence of MDR-TB among previously treated (45.1%) and the second highest among new (8.1%) TB cases in China. In addition, it was observed that the proportions of rifampicin and isoniazid resistance in previously treated (56.0% versus 59.3%) and new (12.2% versus 14.5%) TB cases from the Zunyi area were similar (Table 1) , which indicated that isoniazid resistance might be related to rifampicin resistance and that screening for rifampicin resistance could be used as a marker for the detection of MDR-TB. Since isoniazid has not been widely used as monotherapy for latent TB in China, this could explain the relative lack of single resistance to isoniazid in new TB cases observed in this study. It is obvious that percentages of TB cases with resistance to any of the four drugs in the Zunyi area were much higher than those from other provinces among previously treated TB cases ( Table 1 ), suggesting that the Zunyi area of Guizhou province is one of the worst-affected areas in China and should be included in future surveillance of drug resistance in tuberculosis to better represent the prevalence of MDR-TB in China.
To compare our results with those from other high-burden countries, such as India and Russia, we selectively included in Table 1 four studies with the highest proportions of MDR among previously treated patients (from 49% in Haryana to 38.2% in Rajasthan) out of the eight studies from India, 4 five countries with the highest proportions of MDR among new TB cases (from 14.4% in Latvia to 4.0% in Ivanovo Oblast) from 35 countries that participated in the global surveillance (1994 -97), 5 and five countries with the highest proportions of MDR among new TB cases (from 22.3% in Azerbaijan to 14.8% in Uzbekistan) out of 83 countries/territories surveyed between 2002 and 2007. 6 Comparison of the results shows that the Zunyi area of Guizhou Province, China, has the highest rate of TB cases resistant to ethambutol among previously treated patients (41.8%), and is one of the top 10 areas in the world in terms of the estimated proportion of MDR-TB cases among previously treated TB cases. Consequently, more surveillance should be conducted in the Zunyi area to monitor the trend of MDR-TB transmission, improve the treatment outcomes of TB patients and control the spread of drug-resistant TB, especially MDR-TB. Sir, Recently, van den Boogaard et al. 1 reported that the rate of fluoroquinolone-resistant Mycobacterium tuberculosis in Tanzania was as low as 0.7% (2/291) and that resistance was not related to previous exposure to fluoroquinolones. In our previous study conducted in northern Taiwan, we found that patients of younger age had a higher rate of anti-tuberculosis (TB) drug resistance than patients of advance aged. 2 However, few studies have evaluated the characteristics of patients with ofloxacin-resistant M. tuberculosis in Taiwan. Therefore, we performed this study to determine the risk factors associated with ofloxacin resistance among patients with TB in Taiwan.
This study was conducted at the National Taiwan University Hospital, a 2500-bed tertiary care centre in northern Taiwan. Isolates obtained from patients who had a culture positive for M. tuberculosis at the hospital during the period January 2005 to December 2010 were included in this retrospective analysis. A nonduplicate isolate was defined as a single isolate collected for evaluation from a single patient who visited the hospital. If a patient had multiple isolates, only the first isolate was analysed. All specimens were processed and pretreated as described previously. 3 Testing of susceptibility to anti-TB drugs, including isoniazid (0.2 and 1.0 mg/ L), rifampicin (1 mg/L), ethambutol (5 mg/L), ofloxacin (1 mg/L), streptomycin (2 and 10 mg/L), rifabutin (0.5 mg/L), ethionamide (5 mg/L) and para-aminosalicylic acid (PAS) (2 mg/L), was performed. 3 Drug resistance was defined as resistance to isoniazid
During the study period, a total of 2693 non-duplicate isolates that had been isolated during the 6 year period were analysed. Among them, isoniazid resistance was found in 359 (13.3%) isolates and rifampicin resistance in 112 (4.2%). In addition, 106 (3.9%) isolates were resistant to ethambutol and 269 (10.0%) isolates were resistant to streptomycin. Overall, 89 (3.3%) isolates were considered multidrug-resistant (MDR) M. tuberculosis, and 36 (1.34%) of the isolates were resistant to ofloxacin. Associations between demographic characteristics, ofloxacin-resistant M. tuberculosis and MDR M. tuberculosis are shown in Table 1 . We found that persons 34 to ,44 years of age were more likely to have an ofloxacin-resistant M. tuberculosis strain than persons in any other age subgroup, including elderly patients (patients aged ≥64 years). A total of 5 of 36 ofloxacin-resistant isolates were collected from non-respiratory specimens, including two specimens from pleural fluid, two from urine and one from CSF. Furthermore, among 36 ofloxacin-resistant M. tuberculosis isolates, 28 (77.8%) were proven to be MDR M. tuberculosis, and only 8 (22.2%) isolates were susceptible to all of the first-line anti-TB drugs tested. The resistance rates among the second-line anti-TB drugs were 33.3% for PAS, 13.9% for ethionamide and 47.2% for rifabutin.
Huang et al. 4 demonstrated that the rate of fluoroquinolone resistance increased markedly from 7.7% [95% confidence interval (CI) 7.14%-14.13%] during the period 1995-97 to 22.2% (95% CI 20.0%-30.0%) during the period 1998-2000. The resistance rate to ofloxacin among M. tuberculosis isolates in this study was only 1.34%, which is only marginally higher than the resistance rate to ciprofloxacin among M. tuberculosis isolates reported by van den Boogaard et al. 1 (0.7%). Although susceptibility testing of ciprofloxacin was not performed in the present study, susceptibility profiles among M. tuberculosis isolates have been reported to be similar between ofloxacin and ciprofloxacin. 5 Therefore, we suggest that antimicrobial resistance among M. tuberculosis isolates be monitored at different sites.
